Myocardial Ischemia – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Myocardial Ischemia – Pipeline Review, H1 2017’, provides an overview of the Myocardial Ischemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Myocardial Ischemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Myocardial Ischemia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Myocardial Ischemia

The report reviews pipeline therapeutics for Myocardial Ischemia by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Myocardial Ischemia therapeutics and enlists all their major and minor projects

The report assesses Myocardial Ischemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Myocardial Ischemia

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Myocardial Ischemia

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Myocardial Ischemia pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Angionetics Inc

Bayer AG

Cellmid Ltd

CohBar Inc

Lixte Biotechnology Holdings Inc

NoNO Inc

Omniox Inc

Pathfinder Cell Therapy Inc

Shire Plc

Symic Biomedical Inc

ViroMed Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Myocardial Ischemia - Overview

Myocardial Ischemia - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Myocardial Ischemia - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Myocardial Ischemia - Companies Involved in Therapeutics Development

Angionetics Inc

Bayer AG

Cellmid Ltd

CohBar Inc

Lixte Biotechnology Holdings Inc

NoNO Inc

Omniox Inc

Pathfinder Cell Therapy Inc

Shire Plc

Symic Biomedical Inc

ViroMed Co Ltd

Myocardial Ischemia - Drug Profiles

AB-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

alferminogene tadenovec - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AntimiR-199a - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BAY-606583 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CMK-103 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EP-80317 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Humanin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LB-100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OMX-4.80 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Pathfinder Cells - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptagon - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PMC-6 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Inhibit CXCL for Pancreatitis, Cardiovascular and Immunology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SB-030 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Myocardial Ischemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Myocardial Ischemia Reperfusion Injury - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize TRPM7 for Oncology, Ophthalmology, Cardiovascular and Central nervous System Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Mst1 for Myocardial Ischemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Cardiovascular Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VM-202 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Myocardial Ischemia - Dormant Projects

Myocardial Ischemia - Discontinued Products

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Myocardial Ischemia, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Myocardial Ischemia – Pipeline by Angionetics Inc, H1 2017

Myocardial Ischemia – Pipeline by Bayer AG, H1 2017

Myocardial Ischemia – Pipeline by Cellmid Ltd, H1 2017

Myocardial Ischemia – Pipeline by CohBar Inc, H1 2017

Myocardial Ischemia – Pipeline by Lixte Biotechnology Holdings Inc, H1 2017

Myocardial Ischemia – Pipeline by NoNO Inc, H1 2017

Myocardial Ischemia – Pipeline by Omniox Inc, H1 2017

Myocardial Ischemia – Pipeline by Pathfinder Cell Therapy Inc, H1 2017

Myocardial Ischemia – Pipeline by Shire Plc, H1 2017

Myocardial Ischemia – Pipeline by Symic Biomedical Inc, H1 2017

Myocardial Ischemia – Pipeline by ViroMed Co Ltd, H1 2017

Myocardial Ischemia – Dormant Projects, H1 2017

Myocardial Ischemia – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Myocardial Ischemia, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports